Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution

American Journal of Hematology

Volumn 88, Issue 2, 2013, Pages 120-129

  Bernasconi, Paolo ^a   Klersy, Catherine ^b   Boni, Marina ^a   Cavigliano, Paola Maria ^a   Dambruoso, Irene ^a   Zappatore, Rita ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEW COMPREHENSIVE CYTOGENETIC SCORING SYSTEM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; WORLD HEALTH ORGANIZATION;

AGED; CHROMOSOME ABERRATIONS; COHORT STUDIES; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

EID: 84872951617     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23369     Document Type: Article

References (46)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia: rational and important changes. Blood 2009;114:937-951.
2. Odenicke O, LeBeau MM The dawn of the molecular era of the myelodysplastic syndromes. N Eng J Med 2011;364:2545-2546.
3. Mufti GJ, Stevens JR, Oscier DG, et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425-433.
4. Sanz GF, Sanz MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
5. Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-59.
6. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993;7:1315-1323.
7. Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicentric study in Japan. Leukemia 1993;7:499-508.
8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
9. Solé F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br J Haematol 2000;108:346-356.
10. Solè F, Luno C, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005;90:1168-1178.
11. Bernasconi P, Klersy C, Boni M, et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: A study on 331 patients from a single institution. Leukemia 2005;19:1424-1431.
12. Bernasconi P, Klersy C, Boni M, et al. WHO classification in combination with cytogenetic markers improve the prognostic stratification of patients with de novo primary myelodysplastic syndromes (MDS). Br J Haematol 2007;137:193-205.
13. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007;110:4385-4395.
14. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
15. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndromes that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
16. Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1, 029 patients with primary myelodysplastic syndromes: A report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008;113:3331-3340.
17. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-829.
18. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012;120:2454-2465; doi:10.1182/blood-2012-03-420489.
19. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:3376-3382; doi/10.1200/jco.2011.40.737.
20. Belli CB, Bengió R, Aranguren PN, et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients. Am J Hematol 2011;86:540-545.
21. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the International Prognostic Scoring System. J Clin Oncol 2011;29:1963-1970.
22. Bacher U, Kern W, Alpermann T, et al. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics. Leukemia 2011;25:1361-1364.
23. Bacher U, Kern W, Alpermann T, et al. Prognoses of MDS subtypes RARS, RCMD, RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leukemia Res 2012;36:826-831; dx.doi.org/10.1016/j.leukres.2012.04.003.
24. Tong WG, Quintás-Cardama A, Kadia T, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 2012;118:4462-4470; doi:10.1002/cncr.27420.
25. Platzbecker U, Santini V, Mufti GJ, et al. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop. Leukemia Res 2012;36:264-270.
26. Gondek LP, Tiu RV, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD and MDS-derived AML. Blood 2008;111:1534-1542.
27. Maciejewski JP, Tiu RV, O'Keefe CL Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol 2009;146:479-488.
28. Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117:4552-4560.
29. Tiu RV, Visconte V, Traina F, et al. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011;6:126-135.
30. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011;29:504-515.
31. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Eng J Med 2011;364:2496-2506.
32. Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: Update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010;34:1576-1588.
33. Schaffer LG, Slovak ML, Campbell LJ, editors. An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 2009.
34. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure times. Controlled Clinical Trials 1996;17:343-346.
35. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
36. Jerez A, Sugimoto Y, Makishima H, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 2012;119:6109-6117; doi:10.1182/blood-2011-12-397620.
37. Cordoba I, González-Porras JR, Nomdedeu B, et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer 2012;118:127-133.
38. Hussain FTN, Nguyen EP, Raza S, et al. Sole abnormalities of chromosome 7 in myeloid malignancies: Spectrum, histopathologic correlates, and prognostic implications. Am J Hematol 2012;87:684-686.
39. Sanada M, Uike N, Ohyashiki K, et al. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. Leukemia 2007;21:992-997.
40. Slovak ML, O'Donnell M, Smith DD, Gaal K. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS. Cancer Genet Cytogenet 2009;193:78-85.
41. Sekeres MA. Myelodysplastic Syndromes: It is all in the genes. J Clin Oncol 2012;30:774-776.
42. Beverstock GC, Ploem JE, Wessels H, et al. Trisomy 13 and myelodysplastic syndrome. Cancer Genet Cytogenet 1990;48:179-182.
43. Dicker F, Haferlach C, Kern W, et al. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2009;110:1308-1316.
44. Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011;25:110-120.
45. Jerez A, Gondek LP, Jankowska AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol 2012;30:1343-1349.
46. Pardanani A, Tefferi A Cytogenetic risk stratification in myelodysplastic sindrome: Are we there yet? J Clin Oncol 2012;30:2703.